Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 19/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506464 | 0.94 | WEE1 (0.59) | WEE1 | |
| SCHEMBL21373333 | 0.94 | WEE1 (0.59) | WEE1 | |
| Potrasertib SCHEMBL27123597 | 0.92 | WEE1 (0.63) | WEE1EGFR | |
| Potrasertib SCHEMBL21373352 | 0.92 | WEE1 (0.63) | WEE1EGFR | |
| Potrasertib SCHEMBL23246139 | 0.92 | WEE1 (0.63) | WEE1EGFR | |
| Potrasertib SCHEMBL29506543 | 0.92 | WEE1 (0.63) | WEE1EGFR | |
| Potrasertib SCHEMBL29859319 | 0.92 | WEE1 (0.63) | WEE1EGFR | |
| SCHEMBL21373291 | 0.91 | WEE1 (0.64) | WEE1 | |
| SCHEMBL29506452 | 0.91 | WEE1 (0.64) | WEE1 | |
| SCHEMBL21373320 | 0.90 | WEE1 (0.58) | WEE1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118338905-A | Use of Wee1 kinase inhibitors in the treatment of cancer | 上海瑛派药业有限公司 | 2024-07-12 | — | — | CN | claimed |
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | Impact Therapeutics (Shanghai), Inc (CN) | 2024-03-21 | — | — | US | claimed |
| CN-117202908-A | Use of Wee1 kinase inhibitors in the treatment of cancer diseases | 上海瑛派药业有限公司 | 2023-12-08 | — | — | CN | claimed |
| WO-2023093840-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-06-01 | — | — | WO | claimed |
| WO-2022188802-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2022-09-15 | — | — | WO | claimed |
| CN-118338905-A | Use of Wee1 kinase inhibitors in the treatment of cancer | 上海瑛派药业有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | Impact Therapeutics (Shanghai), Inc (CN) | 2024-03-21 | — | — | US | disclosed |
| US-20240010655-A1 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | Impact Therapeutics (Shanghai), Inc (CN) | 2024-01-11 | — | — | US | disclosed |
| CN-117202908-A | Use of Wee1 kinase inhibitors in the treatment of cancer diseases | 上海瑛派药业有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023093840-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022188802-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2022-09-15 | — | — | WO | disclosed |
| WO-2021073491-A1 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | 上海瑛派药业有限公司 | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | WEE1, WEE2, EZH2 | WEE1 1/4885EGFR 554/4885 |
| US-20240010655-A1 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | WEE1, WEE2, NME1 | WEE1 1/4885EGFR 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.